Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | AHR | P35869 | 3/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10828352 | 0.84 | AHR (0.51) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL26021808 | 0.81 | MAOB (0.39) | MAOBAHRPDE3BPDE3AGAA | |
| SCHEMBL688889 | 0.81 | CES1 (0.56) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL20214 | 0.78 | PDE3B (0.66) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL31040124 | 0.78 | PDE3B (0.66) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL6981292 | 0.77 | AHR (0.51) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL6980695 | 0.77 | GAA (0.48) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL14333290 | 0.76 | MAOB (0.71) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL28346887 | 0.76 | GAA (0.52) | MAOBAHREIF2AK2PDE3BPDE3A | |
| SCHEMBL27691373 | 0.76 | MAOB (0.50) | MAOBAHREIF2AK2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MAOB 775/4885AHR 3678/4885EIF2AK2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.